Urine sample can be used for diagnosis in prostate cancer patients.

Urine is part of the body’s excretory system and contains numerous prostate cancer-specific biomarkers. Small molecules, prostate cancer cells, proteins, cfDNA, RNA, and exosomes can be detected in the urine. Additionally, our company has optimized processes during the early stages of product development to enable detection of biomarkers in urine.

They will not affect the test results.

Our company has added a non-human DNA interference sequencing analysis process to mitigate the impact of microbial DNA on test results. We optimized sample collection, preservation, and extraction procedures during the early stages of research and development, and have successfully extracted free DNA from both hematuria and normal urine.

100 ml of first morning urine should be collected using the specialized sampling kit offered by AcornMed and stored and transported at 2ºC to 30ºC.

It can be used for the diagnosis of patients with inconclusive imaging findings.

During clinical diagnosis of urothelial carcinoma, imaging can identify the presence of space-occupying lesions in a significant portion of patients. However, for patients whose condition cannot be confirmed by imaging, urine cytology, and cystoscopy, our urine tests can provide additional clinical confirmation.

During the clinical diagnosis of prostate cancer, a significant number of patients have Prostate Imaging-Reporting and Data System (PI-RADS) score of 3 and a high false-positive rate in needle biopsy. For these patients, our urine tests can aid in diagnosis and reduce unnecessary needle biopsies. Furthermore, the urine tests can help confirm the diagnosis for patients with inconclusive results from PSA screening, imaging, and needle biopsy.

Clinical studies have demonstrated that MRD can predict recurrence in patients six months earlier compared to imaging. MRD-positive patients may require more frequent follow-ups and monitoring to allow timely detection of recurrence. Furthermore, doctors can develop personalized treatment plans for patients, adjust current therapies, or consider new treatment strategies based on the MRD test results.

Genetic testing can assist in diagnosis, guide the development of personalized treatment plans such as targeted therapy and immunotherapy, enhance treatment efficacy and quality of life, assess patient outcomes, and evaluate genetic risks for both patients and their family members.

Genetic testing can assist physicians in providing patients with personalized cancer treatments, such as chemotherapy, targeted therapy, and immunotherapy.